Obesity Therapy Market Poised for Rapid Evolution
Danish pharmaceutical giant Novo Nordisk is poised to significantly impact India’s obesity therapy market with its recent price reduction for Wegovy, an injectable semaglutide. The company anticipates that this move could increase patient uptake by five to seven times, similar to the success seen with its insulin products. As the market evolves, Novo Nordisk faces competition from lower-priced generics, particularly from rival Eli Lilly & Co., which is also targeting this rapidly growing segment.
Price Reduction and Market Expectations
Novo Nordisk’s decision to cut the price of Wegovy by up to 37% last November aims to enhance accessibility in one of the world’s fastest-growing obesity treatment markets. Vikrant Shrotriya, managing director of Novo Nordisk India, emphasized that the price cut was not a reaction to the impending entry of generics but rather a strategic move to improve patient access. He noted that when the company reduced insulin prices in 2020, patient uptake surged five to seven times over five years. Shrotriya believes that the uptake of semaglutide could accelerate even more rapidly due to the significant unmet need for obesity treatments in India. Patients are also increasingly interested in guidance on foods to eat on Wegovy to maximize treatment outcomes.
Analysts predict that the upcoming patent expiry of semaglutide in March will open up new opportunities for generic versions, potentially generating an additional Rs 5,000 crore in emerging and regulated markets over the next 12 to 15 months. The branded formulation space in India could see an incremental revenue opportunity of Rs 1,000 to 2,000 crore by FY27, according to a Systematix analyst.
Competitive Landscape and Future Plans
As Novo Nordisk prepares for increased competition with the anticipated entry of generics, Shrotriya acknowledged that the market will evolve rapidly, akin to the adoption of artificial intelligence. He expressed confidence that multiple players entering the market would ultimately benefit patients by improving access and services. Novo Nordisk aims to position itself as the preferred partner for both doctors and patients, focusing on quality, reliability, and education.
In addition to Wegovy, Novo Nordisk introduced Ozempic in India last year, further expanding its portfolio of obesity and diabetes therapies. The company is also preparing to launch an oral version of semaglutide, which received FDA approval in December 2025. The Wegovy pill is set to debut in the U.S. this month, and its launch in India will depend on global uptake and production capacity.
Commitment to the Indian Market
Shrotriya, who has been with Novo Nordisk for 25 years and has served as the managing director in India since 2020, reiterated the company’s long-standing commitment to the Indian market. He highlighted that Novo Nordisk was among the first to establish shared services in India two decades ago. Today, the company boasts the largest diabetes care franchise in the country, with five of its brands ranking among the top 100 in India.
The company’s strategic initiatives and focus on innovation underscore its dedication to addressing the growing obesity crisis in India. As Novo Nordisk continues to navigate the competitive landscape, its efforts to enhance patient access and expand treatment options will play a crucial role in shaping the future of obesity therapy in the region.
Observer Voice is the one stop site for National, International news, Sports, Editor’s Choice, Art/culture contents, Quotes and much more. We also cover historical contents. Historical contents includes World History, Indian History, and what happened today. The website also covers Entertainment across the India and World.
